Skip to main content

Lena Trautmann
Director Investor Relations & Sustainability
T: +49 (0) 6172 608-4105
lena.trautmann@fresenius.com

Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com

Axel Faupel
Director Investor Relations & Sustainability
T: +49 (0) 6172 608-93873
axel.faupel@fresenius.com

Do you have questions regarding our company and our products and services? Our experts will be happy to help. 

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany

T: +49 6172 608-0

Postal address:
Fresenius SE & Co. KGaA
61346 Bad Homburg
Germany

How to get here (PDF, 2.19 MB) Route planner

Nick Stone
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com

Silke Zimmermann
Assistant Investor Relations
T: +49 (0) 6172 608-2464
silke.zimmermann@fresenius.com

Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Stefanie Drees
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com

Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com

Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Felix Klein
Director Investor Relations
T: +49 (0) 6172 608-96484
felix.klein@fresenius.com

Kacper Boborykin
Senior Manager Investor Relations
(US based)
T: +1 224 566 1998
kacper.boborykin@fresenius.com

Mara Sinsel
Senior Manager Investor Relations
T: +49 (0) 6172 608-96538
mara.sinsel@fresenius.com

Luca Thorißen
Senior Manager Investor Relations
T +49 6172 608-97049
luca.thorissen@fresenius.com

Annette Hainz
Manager Investor Relations
T: +49 (0) 6172 608-2604
annette.hainz@fresenius.com

Elisabeth Jung
Manager Investor Relations
T: +49 (0) 6172 608-2421
elisabeth.jung@fresenius.com

Dennis Hofmann
Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Alexandra Graulich
Secretary Corporate Communications
T: +49 (0) 6172 608-2501
alexandra.graulich@fresenius.com

 
Contacts for Corporate Topics

Timo Lindemann
T +49 (0) 6172 608-7939
timo.lindemann@fresenius.com

Leif Heussen
T +49 (0) 6172 608-4030
leif.heussen@fresenius.com

Annette Schönleber
T: +49 (0) 6172 608-96847
annette.schoenleber@fresenius.com

Sabine Polte
T: +49 (0) 6172 608-2395
sabine.polte@fresenius.com

Sarah Greier
T: +49 (0) 6172 608-96215
sarah.greier@fresenius.com

 
Contacts for Fresenius Kabi

Nicole Meier
T +49 (0) 6172 686-2394
nicole.meier@fresenius.com

Tim-Arne Kuehrt
T +49 (0) 6172 686-4112
tim.kuehrt@fresenius.com

 
Contacts for Fresenius Helios

Steffen Rinas
T: +49 (0) 6172 608-6698
steffen.rinas@fresenius.com

Birgit Gugath
T +49 (0) 173 28 12 169
birgit.gugath@helios-gesundheit.de

Ines Balkow
T: +49 (0) 30 52 13 21-421
ines.balkow@helios-gesundheit.de

Franziska Vallentin
T +49 (0) 151 65 21 99 81
franziska.vallentin@helios-gesundheit.de

If you have questions regarding our application process or our career opportunities please contact us at karriere@fresenius.com.

You can find detailed contact information on our careers website.

For information on specific products and services, please directly contact our business segments:

Fresenius Kabi
Infusion therapy, clinical nutrition and transfusion technology

Fresenius Helios (German only)
Hospitals and health care prevention

Joachim Weith
Senior Vice President Governmental Affairs & Public Policy
T: +49 (0) 6172 608-2101
GAPP@fresenius.com

Daniela Eyrich
Team Assistant Governmental Affairs & Public Policy
T: +49 (0) 6172 608-2302
daniela.eyrich@fresenius.com

If you have any questions about sustainability, please contact us at the following address: sustainability@fresenius.com

 

Detailed information on sustainability can be found at Responsibility.

If you have any questions about procurement, please contact us at the following address: zentraleinkauf@fresenius.com 

 

Contact form 

Still not found what you are looking for? Here you can send us a message.

For all press inquiries, please contact our Corporate Communications team.

 

Captcha
Please enter the characters shown in the image.

Sebastian Schlagwein
Head of Group ESG
T: +49 (0) 6172 608-2637
sebastian.schlagwein@fresenius.com

Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Silke Zimmermann
Assistant Investor Relations
T: +49 (0) 6172 608-2464
silke.zimmermann@fresenius.com

Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com

The Fresenius Group consists of several independently operating business units.   Statements reflect analysis performed on products developed by one or several business units.  

2024

Publication Date : 19 December 2024
Update Date: -

Fresenius cybersecurity statement for devices tested against the "OpenSSH" CVE-2024-6387 vulnerability.

Publication Date : 10 April 2024
Update Date: 19 December 2024

Fresenius cybersecurity statement for devices tested against the "BLUFFS" vulnerability.

2023

Publication Date : 24 November 2023
Update Date: -

Fresenius cybersecurity statement for devices tested against the "CVE-2022-45611" vulnerability.

2022

Publication Date : 11 July 2022
Update Date: 19 December 2024

Fresenius cybersecurity statement for devices tested against the "MSDT Follina" vulnerability.

Publication Date : 29 June 2022
Update Date: -

Fresenius cybersecurity statement for devices tested against the "Access:7" vulnerability.

2021

Publication Date : 21 December 2021
Latest Update Date: 09 June 2022

Fresenius cybersecurity statement for devices tested against the "Apache Log4J" vulnerability.

Publication Date : 24 November 2021
Latest Update Date: -

Fresenius cybersecurity statement for devices tested against the "NUCLEUS:13" vulnerability.

Publication Date : 12 October 2021
Latest Update Date: -

Fresenius cybersecurity statement for devices tested against the "INFRA:HALT" vulnerability.

2020

Publication Date : 06 July 2020
Update Date: 09 July 2020

Fresenius cybersecurity statement for devices tested against the "Ripple20" vulnerability.

Submit a report

Do you want to be acknowledged by name in any published document about this vulnerability?
Have you shared this vulnerability with anyone (e.g., disclosed vs. not disclosed)

Vulnerability Details

Infusion Pump|ProductSecurity@fresenius.com,Mark.Weber@fresenius-kabi.com
Transfusions Pump|ProductSecurity@fresenius.com,Mark.Weber@fresenius-kabi.com
Nutritional Pump|ProductSecurity@fresenius.com,Mark.Weber@fresenius-kabi.com
Software|ProductSecurity@fresenius.com
Blood Collection Machine|ProductSecurity@fresenius.com,Mark.Weber@fresenius-kabi.com
Monitoring Solution|ProductSecurity@fresenius.com,Mark.Weber@fresenius-kabi.com
Other|ProductSecurity@fresenius.com

Contact

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
cert@fresenius.com

Subscribe to